Keywords: Novartis, Rasilamlo, Germany, IQWiG, AMNOG, Hypertension

Germany’s IQWiG finds no added benefit for Novartis’ Rasilamlo

Article | 21 February 2012

Print This

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined whether the drug combination aliskiren and amlodipine, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in